$XLV

Nasdaq hits 29,000 as strong jobs data and semiconductor strength drive markets to records, though software stocks tumble on weak guidance.

Billionaire Daniel Loeb's Third Point acquires $TMO stake as company beats Q1 earnings and raises guidance, though stock trades 13.7% below technical averages.

UnitedHealth raises 2026 earnings guidance above $18.25 per share after Q1 beat. Stock rises 3.2% despite overbought signals and Medicare drug coverage challenges.

CDT Equity shares rallied 14.71% to $4.68 Monday despite widening $39.1M losses and late 10K filing, defying sector decline.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

Defensive sectors show conflicting technical signals: Utilities strengthen while Consumer Staples weaken and Health Care forms bearish patterns, creating mixed market outlook.

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.

S&P 500 shows distribution signals with break below 100-day moving average, bearish SPY top amid March volatility and earnings season.

Defensive sectors like utilities and healthcare outperform as investors rotate away from expensive tech stocks, signaling shifting risk appetite in markets.